@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAU9ZDOjSZC9ANyhRLrIBwQcb68PanWZVgwNS10z_th-U> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAU9ZDOjSZC9ANyhRLrIBwQcb68PanWZVgwNS10z_th-U#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix chebi: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=> .
@prefix RNA: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_33697> .
@prefix mgi: <http://www.informatics.jax.org/marker/MGI:> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix mesh: <http://purl.bioontology.org/ontology/MSH/> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 geneProductOf: mgi:96820;
    a RNA: .
  
  sub:_2 occursIn: mesh:D008264, species:10090;
    rdf:object sub:_1;
    rdf:predicate belv:increases;
    rdf:subject chebi:50122;
    a rdf:Statement .
  
  sub:assertion rdfs:label "a(CHEBI:rosiglitazone) -> r(MGI:Lpl)" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_4;
    pav:version "1.4" .
  
  sub:_3 prov:value "Since PPARs have been shown to activate LPL gene expression at the transcriptional level via a PPRE in its promoter [21], the influence of PPAR agonists on LPL gene expression in human macrophages was evaluated The average relative increase of LPL mRNA normalized to control 36B4 mRNA levels, as determined by two independent experiments on different macrophage preparations, was approximately 3-, 4-, 3-, and 3.4-fold for rosiglitazone (50 nM), Wy14643 (20 M), GW2331 (200 nM) and PG-J2 (1 M), respectively";
    prov:wasQuotedFrom pubmed:11852057 .
  
  sub:_4 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:11852057;
    prov:wasDerivedFrom beldoc:, sub:_3 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:30:01.180+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}